Bone and Soft Tissue Tumor Program News and Updates

1 - 10 of 13

FDA Approves Drug for Rare Cancer

Published on in CHOP News

CHOP played an instrumental role in leading one of two clinical trials that led to the approval of Xalkori® for unresectable, recurrent, or refractory ALK-positive IMT.